12:00 AM
 | 
May 10, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/7 cls
Elan Corp. plc (NYSE:ELN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) -10% $6.02
van Renterghem upgraded after the share price fell to around his target of $7.27. He previously expected a surge in the number of reported cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri natalizumab, but believes the downside risk is "now mostly priced in." Elan and Biogen Idec Inc. (NASDAQ:BIIB) market the humanized mAb against integrin alpha(4) to treat multiple sclerosis in the EU and to treat MS and Crohn's disease in the U.S.
Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) JMP Securities Liisa Bayko Upgrade Market outperform (from market perform) -22% $3.57
Bayko also set an $8 target based in part on the potential for Idenix's lead HCV compound, IDX-184, to be "competitive with other HCV nucleosides in development." She noted the antiviral responses observed to date for IDX-184 are similar to those seen for the lower dose of 100 mg of PSI-7977, another nucleoside inhibitor in development...

Read the full 1096 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >